Targeting old bottleneck reveals new anticancer drug strategy

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.